Phase II Trial of bezuclastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy.

TYPE OF SARCOMA: Gastrointestinal stromal tumor (GIST)
DRUG: Bezuclastinib in combination with sunitinib

OVERALL PRINCIPLE INVESTIGATOR:
Candace Haddox, MD
Dana Farber Cancer Institute

CLINICALTRIALS.GOV IDENTIFIER: NCT06208748
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICAL TRIALS

Back to top